Extracts containing CLPs of Bacillus amyloliquefaciens JN68 isolated from chicken intestines exert antimicrobial effects, particularly on methicillin-resistant Staphylococcus aureus and Listeria monocytogenes
- PMID: 27840979
- PMCID: PMC5355721
- DOI: 10.3892/mmr.2016.5900
Extracts containing CLPs of Bacillus amyloliquefaciens JN68 isolated from chicken intestines exert antimicrobial effects, particularly on methicillin-resistant Staphylococcus aureus and Listeria monocytogenes
Abstract
Bacillus amyloliquefaciens JN68, which has been discussed with regards to its antimicrobial activities, was successfully isolated from healthy chicken intestines in the present study. Using the spot-on-the-lawn antagonism method, the preliminary study indicated that a suspension culture of the B. amyloliquefaciens JN68 strain can inhibit the growth of Aspergillus niger and Penicillium pinophilum. Furthermore, the cyclic lipopeptides (CLPs) produced by the B. amyloliquefaciens JN68 strain were further purified through acid precipitation and Bond Elut®C18 chromatography, and their structures were identified using the liquid chromatography‑electrospray ionization‑mass spectrometry (MS)/MS method. Purified CLPs exerted broad spectrum antimicrobial activities on various pathogenic and foodborne bacteria and fungi, as determined using the agar well diffusion method. Listeria monocytogenes can induce listeriosis, which is associated with a high mortality rate. Methicillin‑resistant Staphylococcus aureus (MRSA) is a major pathogenic bacteria that causes nosocomial infections. Therefore, L. monocytogenes and MRSA are currently of great concern. The present study aimed to determine whether B. amyloliquefaciens JN68 extracts could inhibit L. monocytogenes and MRSA. The results indicated that extracts of B. amyloliquefaciens JN68 have CLP components, and can successfully inhibit the growth of L. monocytogenes and MRSA.
Figures




Similar articles
-
Antimicrobial activity and spectroscopic characterization of surfactin class of lipopeptides from Bacillus amyloliquefaciens SR1.Microb Pathog. 2019 Mar;128:374-380. doi: 10.1016/j.micpath.2019.01.037. Epub 2019 Jan 26. Microb Pathog. 2019. PMID: 30695712
-
Exogenous addition of alkanoic acids enhanced production of antifungal lipopeptides in Bacillus amyloliquefaciens Pc3.Appl Microbiol Biotechnol. 2019 Jul;103(13):5367-5377. doi: 10.1007/s00253-019-09792-1. Epub 2019 May 3. Appl Microbiol Biotechnol. 2019. PMID: 31053917
-
Novel amylomacins from seaweed-associated Bacillus amyloliquefaciens as prospective antimicrobial leads attenuating resistant bacteria.World J Microbiol Biotechnol. 2021 Oct 19;37(12):200. doi: 10.1007/s11274-021-03161-9. World J Microbiol Biotechnol. 2021. PMID: 34664128
-
Cyclic lipopeptides as antibacterial agents - potent antibiotic activity mediated by intriguing mode of actions.Int J Med Microbiol. 2014 Jan;304(1):37-43. doi: 10.1016/j.ijmm.2013.08.009. Epub 2013 Sep 4. Int J Med Microbiol. 2014. PMID: 24119568 Review.
-
Prebiotic, Probiotic, Antimicrobial, and Functional Food Applications of Bacillus amyloliquefaciens.J Agric Food Chem. 2020 Dec 16;68(50):14709-14727. doi: 10.1021/acs.jafc.0c06396. Epub 2020 Dec 7. J Agric Food Chem. 2020. PMID: 33280382 Review.
Cited by
-
Antimicrobial activities of Bacillus velezensis strains isolated from stingless bee products against methicillin-resistant Staphylococcus aureus.PLoS One. 2021 May 11;16(5):e0251514. doi: 10.1371/journal.pone.0251514. eCollection 2021. PLoS One. 2021. PMID: 33974665 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous